esophageal cancer
Conditions
Interventions
MRI scan with nano-contrast agent
Sponsors
Radboudumc
Eligibility
Inclusion criteria
Inclusion criteria: • Patients with recently biopsy proven esophageal cancer, who are planned to undergo a esophagectomy with nCRT • Patients with suspected lymph nodes metastases on EUS or CT before nCRT • Age > 18 years • Providing informed consent
Exclusion criteria
Exclusion criteria: • Unable to provide informed consent • Known pregnancy or breastfeeding • Contra-indications for MRI • Contra-indications for USPIO based contrast agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the feasibility and diagnostic accuracy of nano-MRI in detecting locoregional lymph node metastases in patients with esophageal cancer whom underwent nCRT | — |
Secondary
| Measure | Time frame |
|---|---|
| - Diagnostic accuracy of the nano-MRI under anesthesia and controlled mechanical ventilation motion in detecting locoregional lymph node metastases in patients with esophageal cancer whom underwent nCRT - Diagnostic accuracy of the nano-MRI in detecting locoregional lymph node metastases ex-vivo after nCRT - Identify the effect of nCRT on the detection of lymph nodes metastases with nano-MRI - Identify the quantitative effect of anesthesia and controlled mechanical ventilation motion MRI compared with ‘breathhold’ MRI. - Compare the diagnostic accuracy of nano-MRI in detecting lymph node metastases with clinical staging results of esophageal cancer (CT, PET, EUS) | — |
Contacts
Public ContactDidi de Gouw
Radboudumc
Outcome results
None listed